• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Angiogenesis and immune checkpoint dual blockade: Opportunities and challenges for hepatocellular carcinoma therapy

    2022-11-21 09:10:16siQiLiYangYangLinSenYe
    World Journal of Gastroenterology 2022年42期

    si-Qi Li, Yang Yang,Lin-Sen Ye

    Abstract The disease burden related to hepatocellular carcinoma (HCC) is increasing. Most HCC patients are diagnosed at the advanced stage and multikinase inhibitors have been the only treatment choice for them. Recently, the approval of immune checkpoint inhibitors (ICIs) has provided a new therapeutic strategy for HCC. It is noteworthy that the positive outcomes of the phase III clinical trial IMBrave150[atezolizumab (anti-programmed cell death ligand 1 antibody) combined with bevacizumab (anti-vascular endothelial growth factor monoclonal antibody)],showed that overall survival and progression-free survival were significantly better with sorafenib. This combination therapy has become the new standard therapy for advanced HCC and has also attracted more attention in the treatment of HCC with anti-angiogenesis-immune combination therapy. Currently, the synergistic antitumor efficacy of this combination has been shown in many preclinical and clinical studies. In this review, we discuss the mechanism and clinical application of anti-angiogenics and immunotherapy in HCC, outline the relevant mechanism and rationality of the combined application of antiangiogenics and ICIs, and point out the existing challenges of the combination therapy.

    Key Words: Anti-angiogenesis; Immunotherapy; Combination therapy; Vascular endothelial growth factor; Immune checkpoint blockade; Hepatocellular carcinoma

    INTRODUCTION

    According to the statistics from the National Cancer Center of China, the incidence and mortality of hepatocellular carcinoma (HCC) are increasing annually[1]. The World Health Organization (WHO)estimates that, from 2015 to 2030, approximately 10 million people in China will die due to liver cirrhosis and HCC. Although early-stage disease can be cured by surgical removed, transplantation, or interventional therapy, most patients have unresectable disease at the time of diagnosis[2], and current treatments are insufficient to prevent the high metastasis and recurrence rates after HCC treatment.

    Currently, immunotherapy is receiving a great deal of attention in the treatment of tumors. Among the immunotherapy options, immune checkpoint blockade (ICB)-based immunotherapy which reactivates dysfunctional or exhausted T cells has shown excellent efficacy in a variety of solid cancers and hematological tumors[3-7]. However, 50%-80% of cancer patients still do not benefit from immunotherapy, and many of them suffer serious adverse events (AEs) during treatment[8]. In fact, there is still no clear mechanism to explain the tolerance of many cancers to immune checkpoint inhibitors (ICIs).HCC is a solid tumor with complex pathophysiological barriers. It is difficult for external lymphocytes to penetrate and infiltrate into tumor tissue. In addition, the rapidly growing tumor cells release immunosuppressive factors, which result in HCC forming an immunosuppressive immune microenvironment, which greatly limits the efficacy of immunotherapy[9]. In addition, the rapidly growing tumor cells release several factors, which result in HCC forming an immunosuppressive immune microenvironment, that greatly limits the efficacy of immunotherapy[10,11]. Therefore, normalizing tumor vasculature and improving the tumor hypoxic microenvironment is expected to reverse the immunosuppressive microenvironment of HCC and promote HCC immunotherapy.

    The TME is mainly composed of the vasculature, resident or infiltrating immune cells and various stromal cells. Previous studies have shown that abnormal tumor vasculature promotes the formation of an immunosuppressive TME[11]. Therefore, therapies that promote normalization of the vasculature are of great significance for enhancing immunotherapy of HCC. This review outlines measures to normalize the vasculature of HCC and the common immunotherapy regimens for HCC, and further describes and discusses how to normalize the tumor vasculature to improve the efficacy of immunotherapy in HCC(especially ICB). Additionally, we discuss the challenges associated with emerging combinations of vascular normalization therapy and immunotherapy for HCC.

    ABNORMAL ANGIOGENESIS AND VASCULAR NORMALIZATION MEASURES FOR HCC

    Abnormal angiogenesis and vascular endothelial growth factor/vascular endothelial growth factor receptor

    The excessive growth and abnormal proliferation of tumor cells depend on rapid tumor angiogenesis.Tumor angiogenesis not only provides tumor cells with oxygen, nutrients and removes waste, but also serves as a channel for metastasis of tumor cells and immune cell infiltration[12,13]. However,compared with vessels in normal tissues, tumor neo-vessels have obvious aberrations in both structure and function[11]. Leakage is one of the most notable features of tumor vessels. On the one hand, this property can lead to tumor hypoxia and decreased intra-tumoral pH by impairing perfusion, and on the other hand, leakage will increase interstitial pressure in the TME[10]. Tumor cells overcome these harsh conditions through multiple mechanisms to gain a survival advantage[11]. Abnormal vessels limit the circulation of drugs and immune cells into the tumor, thereby limiting anti-tumor activity[11]. The hypoxia and pH reduction in the tumor caused by abnormal vessels will further lead to abnormal neovascularization, forming a vicious circle.

    In the field of cancer research, most studies on angiogenesis has focused on the increased expression of angiogenesis factors [such as vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), fibroblast growth factor (FGF), angiopoietin, hepatocyte growth factor, endoglin (CD105,etc)] and decreased expression of anti-angiogenesis factors, such as angiostatin, endostatin, and thrombospondin 1, which is mainly caused by upregulation of the hypoxia-inducible factor protein.Among these, VEGF/VEGF receptor (VEGFR) axis are widely known to play a major role in vascular abnormalities and are crucial for the occurrence and progression of HCC[14-16]. The VEGF family consists of VEGFA, VEGFB, VEGFC, VEGFD and placental growth factor (PlGF) 1-4, which are involved in tumor angiogenesis (VEGFA, PlGF), maintenance of new blood vessels (VEGFB), lymph-angiogenesis and angiogenesis (VEGFC/D), vascular permeability (VEGFA/C), chemotaxis (VEGFB), migration(VEGFA, PlGF), differentiation (VEGFD) and survival (VEGFA/B/C, PlGF)[17,18]. VEGFR mainly includes VEGFR1, VEGFR2, and VEGFR3[15]. Of these, VEGFR2 is the critical receptor of this family,which is expressed on almost all endothelial cells and is activated by binding to VEGFA, VEGFC or VEGFD, and VEGFA is its major ligand[19]. This binding results in the phosphorylation cascade that triggers downstream cellular pathways, ultimately leading to endothelial cell proliferation and migration, and the formation and branching of new tumor blood vessels[19]. These neo-vessels often manifest as abnormal leaky vasculature, resulting in high interstitial pressure and severe hypoxia or necrosis in tissue regions, further promoting the malignant potential of tumor cells[20]. Previous studies have shown that circulating VEGF levels are increased in HCC, and increased VEGFA has been shown to be associated with angiogenesis in HCC[21,22]. In addition, related studies also observed a positive association between increased local and circulating VEGF and high tumor micro-vessel density with rapid disease progression and decreased survival. These findings support the application of therapies that target the VEGF/VEGFR pathway in HCC[21,22].

    Vascular normalization measures in HCC and targeting of the VEGF/VEGFR axis

    Various molecular and physical mechanisms have been reported to contribute to tumor vascular dysfunction, the most prominent of which is the imbalance of angiogenic signaling mediated by proand anti-angiogenic molecules[11,23]. In normal tissue, this balance is precisely maintained to ensure normal vascular morphology and function[24]. However, during the process of carcinogenesis, this balance usually tends to angiogenesis, and the generated neo-vessels are immature abnormal vessels without complete structure[24]. In view of the key role of the VEGF/VEGFR axis in abnormal angiogenesis of HCC, rational targeting of this axis can promote the normalization of tissue vessels and limit the occurrence and development of HCC.

    In the past few decades, the development of anti-angiogenesis therapy has mainly focused on blocking VEGF[17,18]. Several studies have also focused on blocking VEGF signaling by silencing VEGFA expression at the transcriptional and post-transcriptional levels. For example, Zouet al[25]identified emodin that could greatly increase seryl-tRNA synthetase expression in tripe-negative breast cancer (TNBC) cells, consequently reducing VEGFA transcription, and emodin potently inhibited vascular development of zebrafish and blocked tumor angiogenesis in TNBC-bearing mice, greatly improving the survival. Liet al[26] and Dinget al[27] raised that VEGF small interference RNA can precisely and efficiently silence VEGF expression and block VEGF signal pathway, leading to a significant decrease in tumor blood vessels and suppression of tumor growth and metastasis. However,these studies have only been tested in animals. Preclinical evidence suggests that monotherapy which blocks VEGF reduces micro-vessel density, inhibits tumor growth in many cancerous subcutaneous xenografts, and even inhibits tumor cell metastasis[28,29]. Ferraraet al[30] researched and developed the first anti-angiogenesis inhibitor (bevacizumab), a recombinant humanized monoclonal antibody that blocks VEGFA. Bevacizumab binds to VEGF in the bloodstream, thereby inhibiting the interaction between VEGF and VEGFR. In clinical trials of combination therapy for HCC, multiple lines of evidence suggest that bevacizumab has a potential therapeutic effect[31,32].

    On the other hand, many anti-angiogenesis therapies in HCC focus on targeting VEGFR. Multikinase inhibitors (MKIs) and monoclonal antibodies (mAbs) were developed to inhibit VEGFR and its downstream targets to inhibit endothelial cell proliferation, thereby reducing the nutrient and oxygen supply required by tumors. Currently, the VEGFR-targeted MKIs and mAbs used in advanced HCC mainly include sorafenib, regorafenib, lenvatinib, cabozantinib, and ramucirumab (Table 1).

    Sorafenib is an oral MKI that blocks VEGFR1-3, c-Kit, PDGF receptor (PDGFR)-b, and FMS-like tyrosine kinase-3 (FLT-3)[33]. The phase III clinical trial SHARP showed a 2.8-mo survival advantage for sorafenib over placebo in patients with advanced HCC. This recent study also showed that sorafenib can benefit patients with HCC regardless of etiology, and patients with hepatitis C appeared to experience greater benefit[34]. Treatment-related AEs were more common in the sorafenib group than in the placebo group (80%vs52%), and the incidence of dose reductions and interruptions was high during treatment. The MKI regorafenib also targets VEGFR, RET, c-Kit, B-Raf, FGFR1 and PDGFR[33]. It is the first therapy to demonstrate a survival benefit in advanced HCC patients who have progressed on sorafenib[35]. Fatigue, hypertension, diarrhea and hand-foot skin reactions were common AEs in the regorafenib-treated group. Other analyses showed that the survival benefit of first line sorafenib and second line regorafenib was more than 24 mo[35]. The targets of lenvatinib include VEGFR1-3, FGFR1-4,PDGFRa, RET and c-Kit. Recently, a phase III study of lenvatinibvssorafenib in patients withunresectable HCC showed that overall survival (OS) with lenvatinib was non-inferior to sorafenib[36].The most common AEs in the lenvatinib group were diarrhea, fatigue,etc[36]. It should be noted that patients with tumors with more than 50% hepatic masses or involvement of branches of the main portal vein were excluded from the trial (NCT01761266); thus, further clinical trials should be conducted.Despite this problem, lenvatinib remains the only drug in first-line clinical trials that was positive against the proven active control, sorafenib. In addition to targeting VEGFR2, c-Kit, RET, FLT-3, Tie2,and Axl, cabozantinib has the unique property of inhibiting c-Met, and its potential activity was observed in phase II trials[37]. The subsequent phase III clinical trial, which compared cabozantinib to placebo in advanced HCC, met its primary endpoint of improved OS after up to two prior treatments,one of which included sorafenib[38]. Hypertension, pneumonia were common AEs in the cabozantinib group[38]. Ramucirumab, the mAb that antagonizes VEGFR2, improved OS in a phase III study in patients with sorafenib progression or intolerance with baseline alpha-fetoprotein (AFP) ≥ 400 ng/mL[39]. Hypertension and hyponatremia were the only over grade 3 AEs in patients of the test group[39].Based on the results of the previous phase III study, patients can be selected for treatment based on baseline AFP values. A survival benefit was observed with ramucirumab in a subgroup of patients with higher baseline AFP (400 ng/mL), which is the first positive clinical trial in the biomarker-selected HCC population[39].

    Table 1 Currently approved anti-angiogenic therapy for advanced hepatocellular carcinoma

    IMMUNOTHERAPY IN HCC

    Driven by the success of ICB therapy in melanoma, ICB has been extensively studied in a variety of malignancies including HCC[40,41]. Long-term liver injury or chronic hepatitis infection often leaves the liver in a state of chronic inflammation[42]. Moderate inflammation can defend against pathogens and repair tissue damage, whereas persistent liver inflammation can disturb the microenvironment,thus favoring carcinogenesis. On the one hand, hepatic endocrine cytokines play a key role in tumorigenesis through regulating regulatory T cells (Tregs) that inhibit CD8+T cell activation[43]. It was previously reported that Tregs derived from hepatitis B virus-positive HCC tumors exhibited higher programmed cell death protein 1 (PD-1) expression and superior inhibitory capacity against CD8+T cells. On the other hand, cytotoxic immune populations frequently express markers of exhaustion such as PD-1, cytotoxic t-lymphocyte associated antigen 4 (CTLA-4) and lymphocyte activating gene 3[44].Under normal conditions, these molecules inhibit T cell activation to maintain inflammatory homeostasis, protect tissue integrity, and prevent unnecessary autoimmunity[45]. However, in tumors,expression of these markers of exhaustion is inversely correlated with their function, making them a prime target for ICBs to revitalize and restore the cytotoxic capacity of CD8+T cells[43]. At the same time, the expression of PD-1 and its ligand (PD-L1) in tumor cells is upregulated, and when it binds to PD-1 expressed by T cells activated by tumor infiltration, it induces T cell exhaustion and suppresses the anti-tumor immune activity of these immune cells, thereby enabling tumor cells to evade immunity[46].ICBs generate robust multitarget immune responses and can even induce long-lasting tumor remissions in some patients. Inhibition of the PD-1/PD-L1 interaction reverses the depleted state of these cytotoxic immune cells and reactivates their antitumor activity[46,47]. In HCC, the mAbs pembrolizumab and nivolumab that target PD-1, and nivolumab combined with ipilimumab (a mAb directed against CTLA-4), has been approved in the United States for sorafenib-treated patients, based on promising results from clinical trials[48-50]. A clinical trial confirmed the efficacy and safety of PD-1-targeting immunotherapy in HCC[51]. However, subsequent phase III trials of nivolumabvssorafenib in first-line therapy failed to meet the primary survival endpoints[50,52]. The combination of phase III nivolumab and ipilimumab is currently under evaluation (NCT04039607).

    In the current phase III clinical treatment of HCC, immune combination therapy has attracted considerable attention, especially the combination of ICIs and anti-angiogenic inhibitors (Table 2). Lenvatinib combined with pembrolizumab, bevacizumab combined with atezolizumab (PD-L1-targeting mAb)(T+A combination), and cabozantinib combined with atezolizumab have all obtained encouraging results in clinical studies[53-55]. Of these, the combination of bevacizumab and atezolizumab has been successful in phase III clinical trials of first-line treatment of HCC (IMbrave150). Compared with sorafenib, this combination improved the primary endpoints: OS and progression-free survival, and this combination was shown to be safe and improved quality of life[56]. Hypertension and proteinuria were typical side effects of bevacizumab and were the top two AEs in this test group. Upper gastrointestinal bleeding, another known side effect of bevacizumab, occurred in 7% of patients in this group, and was within the range of previous evaluations of bevacizumab AEs for the treatment of HCC[57,58]. Elevated transaminases and pruritus are common side effects of atezolizumab[32]. As this study applied the usual inclusion criteria in HCC clinical trials and included only Child-Pugh A patients, further clinical trials are pending[32].

    Angiogenesis and immune checkpoint combination blockade in HCC

    As shown above, the success of the phase III trial (IMbrave150) with the combination of atezolizumab and bevacizumab in advanced HCC is groundbreaking as it is the first treatment with a better survival rate than sorafenib since the approval of sorafenib in 2007 and is also the only successful first-line immunotherapy combination therapy for HCC in the world[32]. Antibodies targeting VEGF not only inhibit tumor growth but also reprogram the TME from immunosuppressive to immune activation[8,59]. Based on these findings, PD-1/PD-L1 inhibitors combined with VEGF/VEGFR inhibitors have attracted extensive attention in the treatment of HCC. Next, we will outline the mechanism and rationality of PD-1/PD-L1 inhibitors combined with VEGF/VEGFR inhibitor therapy, and the biomarkers of response to targeted immune combination therapy.

    Mechanism and rationality

    In the tumor area, VEGF released by hypoxic cancer cells promotes tumor cell growth and metastasis by angiogenesis[8]. On the other hand, VEGF can also promote the malignant progression of tumors by affecting the TME (Figure 1). The tumor immune cycle mainly includes seven steps, the release of tumor antigens, the uptake and presentation of tumor antigens by dendritic cells (DCs), the initiation and activation of T cells, the migration of T cells to tumors, the invasion of T cells against tumors, the recognition of tumor cells by T cells, and the attack of tumor cells by T cells[60]. VEGF is involved in almost every step of the tumor immune cycle and finally promotes tumor immune escape[61-64]. VEGF enhances the mobilization and proliferation of immunosuppressive cells, including Tregs, tumorassociated macrophages (TAMs), and myeloid-derived suppressor cells (MDSCs)etc, enhances the release of immunosuppressive cytokines[8,59], and promotes M1-TAMs to M2 type polarization. In addition, Tregs and TAMs release immunosuppressive factors, such as VEGF and angiopoietin 2, which form positive feedback to further promote tumor progression[65]. Furthermore, VEGF inhibits the maturation and antigen presentation of DCs. Thus, even in the presence of neoantigens, VEGF can reduce the proliferation and activation of naive CD8+ cells by inhibiting DCs[65]. VEGF prevents antigen activated CD8+ T cells from infiltrating tumor tissue by promoting the formation of abnormal tumor vessels. In addition, VEGF forms an immunosuppressive TME that inhibits the function of T cells in tumors during the effector phase of the immune response[65]. Therefore, inhibition of VEGF/VEGFR interaction not only normalizes vessels but also enhances antitumor immunity.

    Previous studies have shown that inhibition of VEGF/VEGFR can enhance antitumor immunity.Gabrilovichet al[63] found that the targeted drugs which inhibit VEGF/VEGFR lead to an enhanced antigen-presenting capacity of DCs. In addition, studies also found that these drugs inhibit the production of Tregs, TAMs and MDSCs at tumor sites, and negatively regulate the expression of immunosuppressive cytokines such as transforming growth factor-beta and interleukin-10[66].Therefore, blocking VEGF/VEGFR reprograms the immunosuppressive TME[67]. At the same time, the combination of PD-1/PD-L1 antibody can further enhance the antitumor activity of T cells. First, by reversing the VEGF-mediated suppression of DCs maturation resulting in efficient priming and activation of T cells[67,68]; second, by normalizing tumor vasculature and promoting efficient T cell infiltration into tumors[69]; and third, VEGF/VEGFR inhibitors inhibit the activity of MDSCs, Tregs,and TAMs, leading to the reprogramming of the immunosuppressive microenvironment to immune activation[61]. Finally, PD-1/PD-L1 inhibitors enhance the ability of T cells to attack tumor cells. These four aspects can lead to effective antitumor immunity and tumor growth inhibition. As described above,the use of molecularly targeted drugs against VEGF/VEGFR reactivates the aberrant immunosuppressive TME caused by VEGF, and finally allows the tumor cells to be effectively attacked[60,62]. A recent study of T+A therapy showed that the improved outcome of the combination of bevacizumab and atezolizumab compared with atezolizumab alone was mainly related to higher Tregs expression,suggesting that bevacizumab inhibits VEGF-enhanced antitumor immunity mainly related to inhibiting the function of Tregs[70]. Notably, previous studies have shown that anti-PD-1 therapy can increase tumor blood perfusion by normalizing blood vessels in breast and colorectal cancer models, which is closely related to its antitumor efficacy[71]. These studies form the rationale for the combination of VEGF/VEGFR inhibitors and PD-1/PD-L1 inhibitors.

    Table 2 Phase III clinical trials of combinations of anti-angiogenic inhibitors and immune checkpoint inhibitors in hepatocellular carcinoma

    Figure 1 Vascular endothelial growth factor promotes the formation of an immune suppressive microenvironment. VEGF: Vascular endothelial growth factor; DCs: Dendritic cells; MDSCs: Myeloid-derived suppressor cells; TAMs: Tumor-associated macrophages; Tregs: Regulatory T cells.

    Biomarkers to assess the response of targeted immunotherapy

    A major factor limiting the benefit of angiogenesis and immune checkpoint dual blockade for HCC is the lack of biomarkers to predict patients who can benefit from treatment. PD-L1 expression in tumor specimens was not associated with prognosis in HCC patients treated with nivolumab[48]. This study demonstrated that further comprehensive tumor and stromal immune scores, or tumor gene signatures should be explored. A recent study showed that pre-existing immunity (high expression of CD274, Teffector signature and intra-tumoral CD8+ T cell density) was positively associated with better clinical outcomes with the T+A combination and reduced clinical benefit was associated with a high Treg to effector T cell (Teff) ratio and expression of oncofetal genes (GPC3, AFP)[70]. Hatanakaet al[72] reported that C-reactive protein and AFP could be useful for predicting therapeutic outcomes and treatmentrelated AEs in HCC patients treated with the T+A combination. These results indicate that the clinical studies of bevacizumab combined with atezolizumab, lenvatinib combined with pembrolizumab,cabozantinib combined with atezolizumab and other combination therapies are a valuable platform for the analysis of other potential biomarkers of response to targeted immunotherapy and offer several new possibilities for identifying subpopulations of patients who benefit from these treatments. In several cancers, tumor mutational burden (TMB) and microsatellite instability (MSI) are associated with longer OS after ICB therapy. Considering the low frequency of TMB and MSI in HCC, their predictive applications in HCC are limited. However, it is worth noting that studies have shown that HCC with high TMB and low MSI responded to nivolumab for more than 2 years[73]. Thus, much more research is needed to determine the biomarkers of targeted immunotherapy in HCC.

    CONCLUSION

    The global disease burden of HCC is increasing year by year. According to statistics, the annual incidence of HCC may exceed 1 million cases in the near future, and most patients are in advanced stages at diagnosis. Currently, only reasonable systemic treatment can effectively delay the progression of HCC. This article describes the characteristics and treatment strategies of abnormal angiogenesis in HCC, and briefly reviews the immunotherapy of HCC. The strategy and rationality of angiogenesis and immune checkpoint dual blockade are further discussed. Among these combinatorial strategies, the success of the IMBrave150 clinical trial demonstrated that bevacizumab altered the tumor immune microenvironment, enabling greater responses to ICB, successfully transforming the immunosuppressive TME to an immune-activated microenvironment. Therefore, the efficacy achieved by the combination of anti-PD-1/PD-L1 antibody and VEGF/VEGFR inhibitor may be due to normalization of the TME. In addition to the combination of atezolizumab and bevacizumab, other combination therapies targeting the same mechanism have also received attention. While the clinical development of VEGF/VEGFR-targeted drugs is due to their anti-angiogenesis inhibitory effects, the potential of this class of drugs is as immunomodulators in combination with immunotherapy.

    In the post-sorafenib era of advanced HCC treatment, a great number of combination therapies are being studied. However, one of the biggest challenges with combination therapy is the discovery of predictive biomarkers to accurately identify patients most likely to respond to treatment. In the study of HCC, anti-angiogenesis therapy has been used for more than a decade and ICB has been approved for several years, but these two therapies still lack convincing biomarkers. Therefore, for combination therapy, a better understanding of the mechanism of synergistic therapeutic effect and the discovery of predictive biomarkers will help to design more precise treatment regimens.

    FOOTNOTES

    Author contributions:Li SQ, Yang Y and Ye LS carried out the research for the manuscript and edited all drafts of the paper.

    Supported byGuangdong Basic and Applied Basic Research Foundation, No. 2019A1515110654; the National Natural Science Foundation of China, No. 82103448; and China Organ Transplantation Development Foundation, No. YZLC-2021-003.

    Conflict-of-interest statement:All the authors report no relevant conflicts of interest for this article.

    Open-Access:This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BYNC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is noncommercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

    Country/Territory of origin:China

    ORCID number:Yang Yang 0000-0003-4981-4745; Lin-Sen Ye 0000-0001-9632-1949.

    S-Editor:Wang JJ

    L-Editor:A

    P-Editor:Wang JJ

    午夜精品一区二区三区免费看| 色吧在线观看| 亚洲乱码一区二区免费版| 中文亚洲av片在线观看爽| 在线国产一区二区在线| 免费观看精品视频网站| 亚洲av不卡在线观看| 久久人人爽人人片av| 一级毛片我不卡| 一区二区三区免费毛片| 岛国在线免费视频观看| 又粗又硬又长又爽又黄的视频 | 欧美精品一区二区大全| 九九在线视频观看精品| 九草在线视频观看| 亚洲国产日韩欧美精品在线观看| 日本一本二区三区精品| 成人亚洲精品av一区二区| 婷婷色av中文字幕| 色视频www国产| 乱系列少妇在线播放| 亚洲国产色片| 亚洲欧美日韩高清专用| 一个人观看的视频www高清免费观看| 青春草亚洲视频在线观看| 精品久久久久久久久亚洲| 天堂中文最新版在线下载 | 最近2019中文字幕mv第一页| 国产成人影院久久av| 久久午夜福利片| 国产黄片视频在线免费观看| 我要搜黄色片| 精品午夜福利在线看| 亚洲成人中文字幕在线播放| 少妇人妻一区二区三区视频| 又粗又爽又猛毛片免费看| 国产乱人视频| 日日啪夜夜撸| 99国产极品粉嫩在线观看| 日韩一本色道免费dvd| 久久热精品热| 精品一区二区三区人妻视频| 精品一区二区三区人妻视频| 成年女人看的毛片在线观看| h日本视频在线播放| 国产精品国产高清国产av| 搞女人的毛片| av在线亚洲专区| 日韩成人伦理影院| 亚洲人成网站在线观看播放| 成人午夜精彩视频在线观看| 人人妻人人看人人澡| 一级毛片aaaaaa免费看小| 99精品在免费线老司机午夜| av专区在线播放| 欧美最黄视频在线播放免费| 亚洲在线观看片| 精品久久久噜噜| 日韩视频在线欧美| 精品国内亚洲2022精品成人| 美女被艹到高潮喷水动态| 午夜精品一区二区三区免费看| 中文字幕久久专区| 日韩大尺度精品在线看网址| 黄色欧美视频在线观看| 又黄又爽又刺激的免费视频.| 又爽又黄a免费视频| 国产精品永久免费网站| 亚洲国产精品久久男人天堂| 中文字幕免费在线视频6| 国产一级毛片在线| 成熟少妇高潮喷水视频| 极品教师在线视频| 亚洲欧美精品综合久久99| 如何舔出高潮| 老司机福利观看| 晚上一个人看的免费电影| 午夜福利成人在线免费观看| 高清毛片免费看| 直男gayav资源| av在线老鸭窝| 日韩视频在线欧美| 日韩一区二区视频免费看| 国产精品电影一区二区三区| 欧美最黄视频在线播放免费| 可以在线观看毛片的网站| 美女被艹到高潮喷水动态| 中文字幕av在线有码专区| 久久亚洲国产成人精品v| 精品少妇黑人巨大在线播放 | 小蜜桃在线观看免费完整版高清| 天堂av国产一区二区熟女人妻| 天堂av国产一区二区熟女人妻| 亚洲人成网站在线观看播放| 亚洲无线观看免费| 岛国毛片在线播放| 白带黄色成豆腐渣| 国语自产精品视频在线第100页| 一级黄色大片毛片| 夜夜看夜夜爽夜夜摸| 亚洲一区二区三区色噜噜| 精品人妻偷拍中文字幕| 国产三级在线视频| 18禁黄网站禁片免费观看直播| 男人舔女人下体高潮全视频| 国产私拍福利视频在线观看| 哪里可以看免费的av片| 色综合站精品国产| 偷拍熟女少妇极品色| 超碰av人人做人人爽久久| 我要搜黄色片| 久久午夜福利片| 一边摸一边抽搐一进一小说| 老司机影院成人| 欧美xxxx性猛交bbbb| 一级黄片播放器| 国产老妇伦熟女老妇高清| 久久精品夜色国产| 免费看av在线观看网站| 欧洲精品卡2卡3卡4卡5卡区| 直男gayav资源| 国产成人精品一,二区 | 一个人看的www免费观看视频| av福利片在线观看| 成人特级黄色片久久久久久久| 精品一区二区三区人妻视频| 99国产极品粉嫩在线观看| 精品国产三级普通话版| 99热只有精品国产| 国产精品爽爽va在线观看网站| 中国国产av一级| 国产成人a∨麻豆精品| 老司机影院成人| 最近的中文字幕免费完整| 99久国产av精品| a级毛色黄片| 精品99又大又爽又粗少妇毛片| 国产成人精品一,二区 | 97在线视频观看| 亚洲七黄色美女视频| 99久久精品国产国产毛片| 国产美女午夜福利| 亚洲图色成人| 97超碰精品成人国产| 黄色一级大片看看| 成年女人看的毛片在线观看| 日韩精品青青久久久久久| 精品国产三级普通话版| 国产一区二区在线av高清观看| 青青草视频在线视频观看| 亚洲va在线va天堂va国产| 欧美xxxx性猛交bbbb| 久久久久久久久久久丰满| 国产色婷婷99| 尾随美女入室| 你懂的网址亚洲精品在线观看 | 亚洲中文字幕一区二区三区有码在线看| 22中文网久久字幕| 亚洲精品日韩av片在线观看| 亚洲av.av天堂| 狂野欧美激情性xxxx在线观看| 亚洲aⅴ乱码一区二区在线播放| 国产精品嫩草影院av在线观看| 成人鲁丝片一二三区免费| 国产在视频线在精品| 天堂av国产一区二区熟女人妻| 成人高潮视频无遮挡免费网站| 亚洲第一区二区三区不卡| 亚洲精品久久久久久婷婷小说 | 岛国毛片在线播放| 色哟哟哟哟哟哟| eeuss影院久久| 国产黄a三级三级三级人| а√天堂www在线а√下载| 久久久国产成人免费| 男人狂女人下面高潮的视频| 亚洲在线自拍视频| 色5月婷婷丁香| 亚洲电影在线观看av| 久久欧美精品欧美久久欧美| 久久中文看片网| 中文字幕熟女人妻在线| 欧美激情在线99| 亚洲成人久久爱视频| 精品99又大又爽又粗少妇毛片| 美女被艹到高潮喷水动态| 婷婷亚洲欧美| 国内少妇人妻偷人精品xxx网站| 精品人妻视频免费看| 久久中文看片网| 综合色丁香网| 国产精品久久久久久精品电影小说 | 亚洲四区av| 成人二区视频| 老女人水多毛片| 亚洲性久久影院| h日本视频在线播放| 国产精品一区二区性色av| 国产精品久久久久久亚洲av鲁大| 精华霜和精华液先用哪个| 欧美bdsm另类| 国产一区二区亚洲精品在线观看| 丝袜美腿在线中文| 国产成人aa在线观看| 99久久成人亚洲精品观看| 日韩在线高清观看一区二区三区| 在线a可以看的网站| 国产亚洲5aaaaa淫片| 久久久成人免费电影| 狂野欧美激情性xxxx在线观看| 亚洲va在线va天堂va国产| 久久精品夜色国产| 欧美成人免费av一区二区三区| 亚洲人成网站高清观看| 国产成人一区二区在线| 国产女主播在线喷水免费视频网站 | АⅤ资源中文在线天堂| 一边摸一边抽搐一进一小说| 日本黄色片子视频| 观看免费一级毛片| 欧美日本视频| 麻豆成人av视频| 国产成人精品久久久久久| 婷婷色综合大香蕉| 精品午夜福利在线看| 综合色av麻豆| 一个人观看的视频www高清免费观看| 一进一出抽搐动态| 一本精品99久久精品77| 啦啦啦韩国在线观看视频| 不卡视频在线观看欧美| 天天躁夜夜躁狠狠久久av| 日日撸夜夜添| 亚洲国产欧美人成| 国模一区二区三区四区视频| 国产亚洲欧美98| 久久久精品大字幕| 老熟妇乱子伦视频在线观看| 只有这里有精品99| 亚洲自偷自拍三级| 99久久无色码亚洲精品果冻| 最近2019中文字幕mv第一页| 中文在线观看免费www的网站| 成人永久免费在线观看视频| 日韩一本色道免费dvd| 国产成年人精品一区二区| 成人无遮挡网站| 成年av动漫网址| 久久久久久久久久成人| 蜜臀久久99精品久久宅男| 五月玫瑰六月丁香| 美女内射精品一级片tv| 国产v大片淫在线免费观看| 美女被艹到高潮喷水动态| 日本黄色视频三级网站网址| 少妇丰满av| or卡值多少钱| 久99久视频精品免费| 精品久久久噜噜| 全区人妻精品视频| 美女国产视频在线观看| 卡戴珊不雅视频在线播放| 99久国产av精品| 国产免费男女视频| 亚洲精品亚洲一区二区| 爱豆传媒免费全集在线观看| 好男人视频免费观看在线| 免费看av在线观看网站| 91精品一卡2卡3卡4卡| 在线观看av片永久免费下载| 日韩欧美三级三区| 久久午夜福利片| 一卡2卡三卡四卡精品乱码亚洲| 搞女人的毛片| 天天躁夜夜躁狠狠久久av| 亚洲内射少妇av| 日本一二三区视频观看| 午夜精品国产一区二区电影 | 精品无人区乱码1区二区| 中文字幕久久专区| 久久精品91蜜桃| 免费电影在线观看免费观看| 一区二区三区四区激情视频 | 男女啪啪激烈高潮av片| 国产精品,欧美在线| 性色avwww在线观看| 国产在视频线在精品| 美女脱内裤让男人舔精品视频 | 校园人妻丝袜中文字幕| 精品无人区乱码1区二区| 欧美变态另类bdsm刘玥| 精品人妻偷拍中文字幕| 国产成人福利小说| 午夜爱爱视频在线播放| 国产成人a区在线观看| 你懂的网址亚洲精品在线观看 | 五月伊人婷婷丁香| 美女xxoo啪啪120秒动态图| 非洲黑人性xxxx精品又粗又长| 日韩视频在线欧美| 亚洲中文字幕一区二区三区有码在线看| 高清日韩中文字幕在线| 最后的刺客免费高清国语| 国产精品久久电影中文字幕| 欧美激情久久久久久爽电影| av在线观看视频网站免费| 乱人视频在线观看| 日本撒尿小便嘘嘘汇集6| 免费av观看视频| 人人妻人人澡欧美一区二区| 国国产精品蜜臀av免费| 能在线免费观看的黄片| 赤兔流量卡办理| av在线观看视频网站免费| 听说在线观看完整版免费高清| 久久精品夜色国产| 日韩欧美在线乱码| 欧美又色又爽又黄视频| 噜噜噜噜噜久久久久久91| 亚洲成a人片在线一区二区| 91精品一卡2卡3卡4卡| 亚洲成人精品中文字幕电影| 国产精品女同一区二区软件| 99热这里只有是精品在线观看| 国产伦在线观看视频一区| 深夜a级毛片| 亚洲七黄色美女视频| 欧美极品一区二区三区四区| 少妇高潮的动态图| 午夜a级毛片| 亚洲va在线va天堂va国产| 联通29元200g的流量卡| 国产高潮美女av| a级毛片免费高清观看在线播放| 久久久久性生活片| 亚洲国产日韩欧美精品在线观看| 国产午夜精品久久久久久一区二区三区| 搡老妇女老女人老熟妇| 中文字幕免费在线视频6| 网址你懂的国产日韩在线| 免费不卡的大黄色大毛片视频在线观看 | 蜜桃亚洲精品一区二区三区| 免费看光身美女| 日韩精品有码人妻一区| 美女高潮的动态| 色5月婷婷丁香| av免费观看日本| 嫩草影院入口| 天堂影院成人在线观看| 国产精品久久久久久久电影| 国产男人的电影天堂91| 日韩 亚洲 欧美在线| 亚洲欧美成人精品一区二区| 欧美日本亚洲视频在线播放| 综合色丁香网| 亚洲精品乱码久久久v下载方式| 国产精品国产高清国产av| 久久99热这里只有精品18| 美女cb高潮喷水在线观看| 成人一区二区视频在线观看| 亚洲精品自拍成人| 99九九线精品视频在线观看视频| 特大巨黑吊av在线直播| 女同久久另类99精品国产91| 亚洲国产欧美在线一区| 久99久视频精品免费| 国产伦理片在线播放av一区 | or卡值多少钱| 亚洲av不卡在线观看| 美女脱内裤让男人舔精品视频 | 亚洲精品久久国产高清桃花| 丝袜喷水一区| 午夜福利高清视频| 黄片wwwwww| 一级毛片久久久久久久久女| 成人性生交大片免费视频hd| 成年av动漫网址| 你懂的网址亚洲精品在线观看 | 97超视频在线观看视频| 午夜激情欧美在线| 亚洲,欧美,日韩| 少妇丰满av| 最近手机中文字幕大全| 免费观看精品视频网站| 国产av在哪里看| 最近中文字幕高清免费大全6| 国产久久久一区二区三区| 亚洲国产高清在线一区二区三| 色综合站精品国产| 国产精品伦人一区二区| 在线a可以看的网站| 国产av不卡久久| 色视频www国产| 岛国毛片在线播放| 亚洲av免费在线观看| 国产麻豆成人av免费视频| 亚洲最大成人中文| 在线免费观看的www视频| 三级毛片av免费| 黄色配什么色好看| 精品午夜福利在线看| 免费在线观看成人毛片| 亚洲国产精品合色在线| 高清日韩中文字幕在线| 国产成人aa在线观看| 婷婷亚洲欧美| 亚洲精品色激情综合| 国产日本99.免费观看| www.av在线官网国产| 国产私拍福利视频在线观看| 午夜激情欧美在线| 国产精品国产高清国产av| 黑人高潮一二区| 18禁在线播放成人免费| 欧美一级a爱片免费观看看| 美女被艹到高潮喷水动态| 一个人看视频在线观看www免费| 春色校园在线视频观看| 蜜桃久久精品国产亚洲av| 男女做爰动态图高潮gif福利片| 日本欧美国产在线视频| 中文字幕av在线有码专区| 亚洲成人中文字幕在线播放| 久久6这里有精品| 一本精品99久久精品77| 日本-黄色视频高清免费观看| 久久久成人免费电影| 高清毛片免费观看视频网站| 国内久久婷婷六月综合欲色啪| 黄色日韩在线| 一本—道久久a久久精品蜜桃钙片 精品乱码久久久久久99久播 | 亚洲真实伦在线观看| 亚洲五月天丁香| 国产成人a区在线观看| 黄片无遮挡物在线观看| 日韩欧美精品免费久久| 亚洲人成网站在线观看播放| 国产成人91sexporn| 最近2019中文字幕mv第一页| 麻豆成人av视频| 免费观看a级毛片全部| 六月丁香七月| 乱码一卡2卡4卡精品| 永久网站在线| 九九热线精品视视频播放| 婷婷色av中文字幕| 夫妻性生交免费视频一级片| 免费电影在线观看免费观看| 国产一区二区亚洲精品在线观看| 一个人观看的视频www高清免费观看| 99久久人妻综合| 国产成人精品久久久久久| 九九热线精品视视频播放| 老司机福利观看| 亚洲电影在线观看av| 亚洲av一区综合| 老女人水多毛片| eeuss影院久久| 欧美丝袜亚洲另类| 在线观看免费视频日本深夜| 成人漫画全彩无遮挡| 日韩视频在线欧美| 一区福利在线观看| 韩国av在线不卡| 亚洲一区二区三区色噜噜| 天天躁日日操中文字幕| 91精品一卡2卡3卡4卡| 国产av不卡久久| 亚洲图色成人| 国产精品无大码| 99热全是精品| 亚洲电影在线观看av| 99国产精品一区二区蜜桃av| 99热精品在线国产| 久久精品国产亚洲av香蕉五月| 久久人人爽人人片av| 午夜福利在线观看免费完整高清在 | or卡值多少钱| 真实男女啪啪啪动态图| 26uuu在线亚洲综合色| 日本撒尿小便嘘嘘汇集6| 亚洲成人久久性| 国产精品久久视频播放| 亚洲性久久影院| 国产一区二区激情短视频| av在线老鸭窝| 国产精品一及| 精品99又大又爽又粗少妇毛片| ponron亚洲| 男插女下体视频免费在线播放| 国产探花极品一区二区| 18禁在线播放成人免费| av专区在线播放| 国产精品国产三级国产av玫瑰| 蜜桃久久精品国产亚洲av| 97人妻精品一区二区三区麻豆| 久久精品夜色国产| 天堂中文最新版在线下载 | 搡老妇女老女人老熟妇| 看黄色毛片网站| 亚洲av成人av| 亚洲天堂国产精品一区在线| 五月伊人婷婷丁香| 国产中年淑女户外野战色| 亚洲欧美精品自产自拍| 一区二区三区免费毛片| 亚洲欧美日韩东京热| 青春草亚洲视频在线观看| 赤兔流量卡办理| 国产一区二区激情短视频| 成人综合一区亚洲| 国产精品国产三级国产av玫瑰| 亚洲第一电影网av| 久久亚洲精品不卡| 如何舔出高潮| .国产精品久久| 卡戴珊不雅视频在线播放| 看十八女毛片水多多多| av在线播放精品| 一个人看视频在线观看www免费| 黄色视频,在线免费观看| 欧美最黄视频在线播放免费| 国产成年人精品一区二区| 久久精品国产鲁丝片午夜精品| 亚洲欧洲国产日韩| 亚洲欧美精品综合久久99| 最好的美女福利视频网| 久久精品国产亚洲网站| ponron亚洲| 国产精品一区www在线观看| 寂寞人妻少妇视频99o| 毛片女人毛片| 不卡一级毛片| 成人性生交大片免费视频hd| 男人舔奶头视频| 久久99热6这里只有精品| 精品人妻视频免费看| 女的被弄到高潮叫床怎么办| 精品久久久久久久久亚洲| 成人二区视频| 成人三级黄色视频| 美女高潮的动态| av在线观看视频网站免费| 少妇人妻精品综合一区二区 | 国产精品人妻久久久影院| 国产又黄又爽又无遮挡在线| 国产精品免费一区二区三区在线| 日韩欧美国产在线观看| 国产精品免费一区二区三区在线| 国产 一区 欧美 日韩| 99热只有精品国产| 乱码一卡2卡4卡精品| 国产精品,欧美在线| 一本精品99久久精品77| 久久久久久久久久黄片| 午夜精品一区二区三区免费看| 黑人高潮一二区| 黄色欧美视频在线观看| 国产男人的电影天堂91| 午夜精品一区二区三区免费看| 国产黄a三级三级三级人| 黄色欧美视频在线观看| 国产av不卡久久| 看片在线看免费视频| 亚洲最大成人av| 欧美人与善性xxx| 国产高清有码在线观看视频| 岛国毛片在线播放| 丝袜美腿在线中文| 三级男女做爰猛烈吃奶摸视频| 一本久久中文字幕| 精品熟女少妇av免费看| 最近手机中文字幕大全| 在线天堂最新版资源| 美女cb高潮喷水在线观看| 成年女人看的毛片在线观看| 国内精品宾馆在线| 一区二区三区高清视频在线| 能在线免费观看的黄片| 波多野结衣高清无吗| 日本黄色片子视频| 亚洲成人中文字幕在线播放| 亚洲精品乱码久久久v下载方式| 男女做爰动态图高潮gif福利片| av黄色大香蕉| 五月玫瑰六月丁香| av专区在线播放| 99九九线精品视频在线观看视频| 伊人久久精品亚洲午夜| 99久久无色码亚洲精品果冻| 精品不卡国产一区二区三区| 日本一二三区视频观看| 国产爱豆传媒在线观看| 国产亚洲欧美98| 亚洲精品成人久久久久久| 亚洲久久久久久中文字幕| 免费av毛片视频| 国产成人精品一,二区 | 午夜精品一区二区三区免费看| 麻豆国产97在线/欧美| 国产精品人妻久久久久久| 久久综合国产亚洲精品| 亚洲国产精品合色在线| 精品久久久久久久末码| 成人特级黄色片久久久久久久| 欧美色视频一区免费| 亚洲精品乱码久久久久久按摩| 一级av片app| 美女国产视频在线观看| 亚洲在线自拍视频| 亚洲最大成人av| 99久久九九国产精品国产免费| 美女cb高潮喷水在线观看| 又粗又爽又猛毛片免费看| 国产69精品久久久久777片|